Cassava Sciences | PTIE - Ebitda


Cassava Sciences reported $-11.73M in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
Abbott USD 3.09B 44M Sep/2025
Amgen USD 5.14B 775M Dec/2025
Biogen USD 573.2M 253.7M Dec/2025
Cara Therapeutics USD -2.39M 3.16M Mar/2025
Cassava Sciences USD -11.73M 33.44M Sep/2025
Eisai JPY 30.1B 6.62B Dec/2025
Eli Lilly USD 7.88B 378.1M Sep/2025
Geron USD -9.47M 1.92M Sep/2025
J&J USD 9.52B 389M Sep/2025
Merck USD 8.39B 1.97B Sep/2025
Novartis USD 5.88B 290M Sep/2025
Novavax USD 19.36M 190.79M Dec/2025
Pfizer USD 6.08B 351M Sep/2025
Roche Holding CHF 12.68B 2.36B Jun/2024